VRTX — Vertex Pharmaceuticals Incorporated
$538.60
$-4.02 (-0.74%)
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Market Cap
$136.56B
Forward P/E
27.0x
52-Week Range
N/A
VRTX Price History
Revenue vs. Net Income
$12B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$3.2B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
21.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
3.7x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
3.6%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+0.0%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
